List view / Grid view
In this free-to-view Stem Cells In-Depth Focus, you can find out how computational ('in silico') methods can help to rationally choose bioactive small molecules to improve stem cell differentiation. The differentiation of pluripotent stem cells to hepatocyte-like cells is the focus of a second interesting article...
In this free-to-view LC-MS in-depth focus, we delve into the world of glycans, and how their natural complexity necessitates sophisticated sequencing techniques, while another article aims to demonstrate the versatility of LC-MS and the ease with which it can be combined with a variety of MS systems, focusing particularly on…
14 April 2015 | By Victoria White
Merck has announced that Udit Batra has been appointed to lead the combined life science business of Merck Millipore and Sigma-Aldrich...
26 September 2014 | By Sigma-Aldrich
This pharma webinar discusses the decision to generate iPSC disease models to more efficiently and quickly validate two potential lung cancer targets, as well as considerations for undertaking successful cell engineering projects for high-content screening assay development and target validation.
24 September 2014 | By Sigma-Aldrich
Sigma-Aldrich Corporation’s SAFC® Commercial custom manufacturing services business unit, and Baxter’s BioPharma Solutions business have established a collaborative manufacturing agreement...
24 September 2014 | By Sigma-Aldrich
Merck KGaA , a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors, and Sigma-Aldrich announced that they have entered into a definitive agreement under which Merck KGaA, Darmstadt, Germany, will acquire Sigma-Aldrich for $17.0 billion...
Alongside established drug target classes, innovative approaches are addressing previously undruggable target classes such as protein–protein interactions.
3 February 2014 | By Sigma-Aldrich
This pharma webinar provides an overview of how compound profiling using the PLA® (Proximity Ligation Assay) technology can be used for in situ analysis of protein interactions by high content screening as part of the hit-to-lead workflow, the key advantage being the ability to provide evidence for target engagement of…
3 August 2011 | By kdm communications limited
With increased affordability for CompoZr® ZFNs and the expansion of Knockout ZFNs to include every gene in mice and rats...
22 July 2011 | By kdm communications ltd
Expansion of the CompoZr® Oncology Disease Model portfolio...
5 May 2011 | By kdm communications limited
Exclusive license to develop and commercialize new technology...
12 April 2011 | By kdm communications limited
Sigma Life Science, today announced the signing of an agreement with KBLB...
17 March 2011 | By kdm communications limited
Inititive is in collaboration with The Michael J. Fox Foundation for Parkinson’s Research...
10 March 2011 | By kdm communications limited
Sigma Life Science,has announced the addition of 1,400 new ECACC cell lines to its collection of cell line cultures and services...
24 February 2011 | By kdm communications limited
The new offer, attractively priced to fit within the budget of a typical laboratory...
